In vivo targeting of diabetes-relevant human cell types with rAAV vectors

rAAV 载体体内靶向糖尿病相关人类细胞类型

• 批准号: 8812513
• 负责人: Markus Grompe
• 金额: $ 360.47万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-30 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8812513
• 关键词: Acinar Cell; Alkaline Phosphatase; Alpha Cell; Antioxidants; Autoimmunity; Automobile Driving; Beta Cell; Biliary; Binding; Binding Sites; CDKN1C gene; Capsid; Cells; Clinical; Code; Complementary DNA; DNA Polymerase II; DNA Shuffling; Diabetes Mellitus; Duct (organ) structure; Ductal Epithelium; Elements; Enhancers; Epithelium; Evolution; Gallbladder; Gene Delivery; Generations; Genes; Genetic; Genetic Transcription; Genome; Goals; Hepatocyte; Human; Insulin-Dependent Diabetes Mellitus; Libraries; Liver; Methods; MicroRNAs; Modification; Mutation; Natural regeneration; Pancreas; Pancreatic delta Cell; Pathway interactions; Patients; Property; Proteins; RNA; RNA Sequences; Reagent; Recombinant adeno-associated virus (rAAV); Regulatory Element; Safety; Specificity; Structure of beta Cell of islet; Up-Regulation; Variant; Viral Vector; Xenograft Model; Xenograft procedure; adeno-associated viral vector; cell type; cellular transduction; clinically relevant; gene therapy; in vivo; mutant; neutralizing antibody; novel; oval cell; progenitor; promoter; public health relevance; small hairpin RNA; therapeutic DNA; therapeutic target; transcription factor; transcriptome sequencing; vector

DESCRIPTION (provided by applicant): Clinical implementation of several of the most promising approaches to the treatment of type 1 diabetes will require the ability to perform genetic modifications of specific target cells in human patients in vivo. The pancreatic beta-cell is the most important target and therapeutic opportunities include the induction of regeneration, suppression of autoimmunity and upregulation of anti-oxidant pathways. Several other cell types have potential to be reprogrammed to functional beta-cells by directed fate conversion using transcription factors and microRNAs. This list includes pancreatic acinar cells, biliary duct epithelium of the liver, gall bladder epithelium, pancreatic delta-cells and alpha-cells. The goal f this application is to develop recombinant adeno-associated virus (rAAV) vectors capable of delivering genetic payloads to these target cells in humans efficiently and specifically. rAAV is already being used in several clinical gene therapy applications and has a good safety record. The required precision of gene delivery will be achieved by combining cell-type specific rAAV capsids with gene regulatory elements (promoters, enhancers and microRNA binding sites) that limit expression to only the target cell. rAAV capsid and the regulatory sequences will be optimized for each human cell type using xenograft models.

描述(由申请人提供)：几种最有希望的1型糖尿病治疗方法的临床实施将需要在体内对人类患者的特定靶细胞进行基因修改的能力。胰腺β细胞是最重要的靶点和治疗机会，包括诱导再生、抑制自身免疫和上调抗氧化途径。其他几种类型的细胞也有可能通过使用转录因子和microRNAs进行定向命运转化而重新编程为具有功能的β细胞。该列表包括胰腺腺泡细胞、肝胆管上皮、胆囊腺上皮、胰腺三角洲细胞和α细胞。这项应用的目标是发展重组腺相关病毒(RAAV)载体，能够高效和特异地将基因有效载荷传递到人类的这些靶细胞。RAAV已经在几个临床基因治疗应用中使用，并有良好的安全性记录。通过将特定细胞类型的rAAV衣壳与基因调控元件(启动子、增强子和microRNA结合位点)相结合，可以实现所需的基因传递精度，这些元件将仅限于靶细胞表达。RAAV衣壳和调控序列将使用异种移植模型针对每种人类细胞类型进行优化。